BACK
This post may refer to COVID-19

This post may refer to COVID-19

To access official information about the coronavirus, access CDC - Centers for Disease Control and Prevention.

Psychedelics Company Gets Green Light for PTSD Therapy Study Using MDMA in Canada
www.goodnewsnetwork.org

Psychedelics Company Gets Green Light for PTSD Therapy Study Using MDMA in Canada

Numinus has received Health Canada approval of a study for MDMA-Assisted Therapy for PTSD: here's how the trails will look.

Health

A mental health care company in Canada has been given federal approval to conduct a safety and feasibility study evaluating MDMA-assisted therapy for post-traumatic stress disorder (PTSD).

“We are thrilled that Health Canada has issued its No Objection Letter allowing this important study to proceed and, in doing so, potentially advance Canada toward a legal, regulated system for MDMA-assisted therapy,” said Payton Nyquvest, CEO of Numinus.

“We are gratified that our study will provide safety and outcome data to regulators to support integration of this treatment into mainstream mental health care.”

Click to continue reading

This study has advanced through the pre-implementation stage at Numinus‘ Vancouver clinic and has now received the required federal regulatory approval.

Study preparations are now transitioning into the final stages of training staff, importing medication, and obtaining ethical approval to allow the recruitment of participants according to COVID-19 public health protocols.

During the study, research, medical, and therapist staff at Numinus will collect data on the safety and effectiveness of MDMA-assisted therapy to inform Health Canada and support making MDMA-assisted therapy available to individuals living with PTSD in Canada.

Through the collaboration and study activities, Numinus seeks to create access for patients with no other treatment options and establish the physical, human resource and other infrastructure required to scale up access to MDMA-assisted therapy if federal approvals are ultimately in place.

Dr. Devon Christie, Numinus Medical and Therapeutic Services Director, will serve as the study’s Qualified Investigator and as a study therapist. Dr. Christie is a family physician with a focus in multidisciplinary pain management and a certified Relational Somatic Therapist.